Alexey Eliseev - RXi Pharmaceuticals Chief Business Officer

Executive

Dr. Alexey Eliseev serves as Chief Business Officer of the Company. He was previously the Founder and Chief Executive Officer of MirImmune. Dr. Eliseevs career includes over twenty years of experience in academia, biotechnology industry and VC. He received his Ph.D. in Bioorganic Chemistry from Moscow State University and MBA from the MIT Sloan School of Management. Alexey was working in the U.S. and Europe since 1992. Following three years of postdoctoral research in Germany and in the U.S., he joined the faculty at SUNY Buffalo in 1995 where he was awarded tenure in 2000. In 1999 he cofounded the company Therascope later Alantos Pharmaceuticals, with a number of prominent founders including French Nobel Laureate JeanMarie Lehn. He then became CTO of Alantos and President of Alantoss U.S. division. Alantos was acquired by Amgen in 2007. Dr. Eliseev was also among the founders of AC Immune and Boston BioCom LLC. Over the recent years he has worked with Maxwell Biotech Venture Fund as its Managing Director and ran the investment activity of the fund in the United States. Dr. Eliseev is a member of the board of directors of BioNevia Pharmaceuticals. since 2017.
Age 50
Tenure 7 years
Phone508-767-3861
Webhttp://www.rxipharma.com

RXi Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (96.79) % which means that it has lost $96.79 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (294.79) %, meaning that it created substantial loss on money invested by shareholders. RXi Pharmaceuticals' management efficiency ratios could be used to measure how well RXi Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.

Similar Executives

Showing other executives

EXECUTIVE Age

Tiang TanWestern Digital
54
Cecilia BilesioTenaris SA ADR
N/A
Carolyn BassAsure Software
N/A
Renato CatalliniTenaris SA ADR
58
Paola MazzoleniTenaris SA ADR
43
Claus MorchAwilco Drilling PLC
66
Kate MBARani Therapeutics Holdings
N/A
Gabriel PodskubkaTenaris SA ADR
50
Antonio CapreraTenaris SA ADR
59
Gene ZamiskaWestern Digital
62
Eric GroenRani Therapeutics Holdings
53
Michele BriottaTenaris SA ADR
47
Guillermo MorenoTenaris SA ADR
53
Peter AndrewWestern Digital
N/A
Sergio TosatoTenaris SA ADR
65
Scott DavisWestern Digital
N/A
Arvinder DhallaRani Therapeutics Holdings
N/A
Cathrine HaavindAwilco Drilling PLC
N/A
German CuraTenaris SA ADR
57
Sergio MazaTenaris SA ADR
68
Robert SoderberyWestern Digital
58
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts. RXi Pharmaceuticals operates under Biotechnology classification in USA and is traded on Nasdaq Capital Markets. It employs 15 people. RXi Pharmaceuticals (RXII) is traded on NASDAQ Exchange in USA and employs 15 people.

Management Performance

RXi Pharmaceuticals Leadership Team

Elected by the shareholders, the RXi Pharmaceuticals' board of directors comprises two types of representatives: RXi Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of RXi. The board's role is to monitor RXi Pharmaceuticals' management team and ensure that shareholders' interests are well served. RXi Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, RXi Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Geert Cauwenbergh, President CEO, Director
Robert Bitterman, Director
Pamela Pavco, Chief Devel. Officer
Keith Brownlie, Director
Jonathan Freeman, Independent Director
Gerrit Dispersyn, Chief Development Officer
Curtis Lockshin, Director
Paul Dorman, Independent Director
Alexey Eliseev, Chief Business Officer
Tamara McGrillen, IR Contact Officer

RXi Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is RXi Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Other Consideration for investing in RXi Stock

If you are still planning to invest in RXi Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the RXi Pharmaceuticals' history and understand the potential risks before investing.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume